Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Gen Intern Med ; 36(12): 3869-3874, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34549355

RESUMEN

We present two cases of Babesia-induced splenic injury at a single institution. In the late summer, two patients presented with left-sided abdominal pain radiating to the shoulder. They were both found to have hemolytic anemia, thrombocytopenia, and acute splenic infarction on imaging. Blood smears showed intracellular ring forms consistent with Babesia spp. and low parasitemia (<1%). Diagnosis was confirmed by PCR for Babesia microti. Both patients improved with azithromycin and atovaquone, without blood products or surgical intervention. Several weeks following treatment, repeat blood smears revealed no parasites. Splenic infarct and hemorrhage have been previously reported as rare complications of babesiosis. However, given the steady rise in Babesia microti cases in the USA, even these rare complications will become more prevalent. We review both the diagnosis and management of Babesia-induced splenic complications, which can be challenging in patients with low-level parasitemia. Clinicians should consider babesiosis as a cause of atraumatic splenic injury.


Asunto(s)
Babesia microti , Babesiosis , Azitromicina , Babesiosis/complicaciones , Babesiosis/diagnóstico , Babesiosis/tratamiento farmacológico , Humanos , Parasitemia
2.
Sci Rep ; 10(1): 10505, 2020 Jun 29.
Artículo en Inglés | MEDLINE | ID: mdl-32601328

RESUMEN

Performance of solar PV diminishes with the increase in temperature of the solar modules. Therefore, to further facilitate the reduction in cost of photovoltaic energy, new approaches to limit module temperature increase in natural ambient conditions should be explored. Thus far only approaches based at the individual panel level have been investigated, while the more complex, systems approach remains unexplored. Here, we perform the first wind tunnel scaled solar farm experiments to investigate the potential for temperature reduction through system-level flow enhancement. The percentage of solar irradiance converted into electric power depends upon module efficiency, typically less than 20%. The remaining 80% of solar irradiance is converted into heat, and thus improved heat removal becomes an important factor in increasing performance. Here, We investigate the impact of module inclination on system-level flow and the convective heat transfer coefficient. Results indicate that significant changes in the convective heat transfer coefficient are possible, based on wind direction, wind speed, and module inclination. We show that 30-45% increases in convection are possible through an array-flow informed approach to layout design, leading to a potential overall power increase of ~5% and decrease of solar panel degradation by +0.3%/year. The proposed method promises to augment performance without abandoning current PV panel designs, allowing for practical adoption into the existing industry. Previous models demonstrating the sensitivity to convection are validated through the wind tunnel results, and a new conceptual framework is provided that can lead to new means of solar PV array optimization.

3.
Am J Med ; 133(4): 452-462.e4, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31647915

RESUMEN

BACKGROUND: True allergy to penicillin is rare, despite the high frequency with which it is reported. While most patients reporting penicillin allergy are not prone to anaphylaxis, it is not currently known what percentage of these patients will tolerate dose challenges of penicillin-based antibiotics. This review aims to determine the rate of tolerance in patients reporting penicillin allergy when challenged with penicillin-based antibiotics. METHODS: We searched MedLine, Embase, and Cochrane Library for publications with English language translations between the years 2000 and 2017. We included randomized controlled trials, quasi-experimental, and observational studies of participants reporting penicillin allergy who received at least one systemic dose of a penicillin in the form of a drug challenge. At least 2 independent reviewers extracted data from included studies and assessed the quality of each included study. To generate primary outcome data, we calculated a summary estimate rate of penicillin tolerance from a pooled proportion of participants receiving penicillin with no adverse effects. RESULTS: Initial literature search yielded 2945 studies, of which 23 studies were ultimately included in our review; 5056 study participants with reported history of penicillin allergy were challenged with a penicillin. After weighting for study sample size, a pooled average of 94.4% (95% confidence interval, 93.7%-95%) of participants tolerated the dose challenge without any adverse reaction. CONCLUSION: Misrepresented penicillin allergy drives unnecessary use of alternative antibiotics, which may be less effective, more toxic, and more expensive than using penicillin. In addressing the problem of penicillin allergy over-diagnosis, evaluation should go beyond risk for type 1 hypersensitivity. Our data suggest that 94.4% of 5056 participants with reported penicillin allergy determined to be clinically appropriate for allergy evaluation tolerated repeat administration of penicillin-based antibiotics without any adverse reactions. This review generates meaningful information useful to clinical predictive analytics, in evaluating and managing patients with a reported history of penicillin allergy.


Asunto(s)
Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/prevención & control , Penicilinas/efectos adversos , Antibacterianos/administración & dosificación , Hipersensibilidad a las Drogas/etiología , Humanos , Penicilinas/administración & dosificación
4.
J Gen Intern Med ; 34(11): 2451-2459, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31432439

RESUMEN

BACKGROUND: The Affordable Care Act and the introduction of accountable care organizations (ACOs) have increased the incentives for patients and providers to engage in preventive care, for example, through quality metrics linked to disease prevention. However, little is known about how ACOs deliver preventive care services. OBJECTIVE: To understand how Medicare ACOs provide preventive care services to their attributed patients. DESIGN: Mixed-methods study using survey data reporting Medicare ACO capabilities in patient care management and interviews with high-performing ACOs. PARTICIPANTS: ACO executives completed survey data on 283 Medicare ACOs. These data were supplemented with 39 interviews conducted across 18 Medicare ACOs with executive-level leaders and associated clinical and managerial staff. MAIN MEASURES: Survey measures included ACO performance, organizational characteristics, collaboration experience, and capabilities in care management and quality improvement. Telephone interviews followed a semi-structured interview guide and explored the mechanisms used, and motivations of, ACOs to deliver preventive care services. KEY RESULTS: Medicare ACOs that reported being comprehensively engaged in the planning and management of patient care - including conducting reminders for preventive care services - had more beneficiaries and had a history of collaboration experience, but were not more likely to receive shared savings or achieve high-quality scores compared to other surveyed ACOs. Interviews revealed that offering annual wellness visits and having a system-wide approach to closing preventive care gaps are key mechanisms used by high-performing ACOs to address patients' preventive care needs. Few programs or initiatives were identified that specifically target clinically complex patients. Aside from meeting patient needs, motivations for ACOs included increasing patient attribution and meeting performance targets. CONCLUSIONS: ACOs are increasingly motivated to deliver preventive care services. Understanding the mechanisms and motivations used by high-performing ACOs may help both providers and payers to increase the use of preventive care.


Asunto(s)
Organizaciones Responsables por la Atención/organización & administración , Servicios Preventivos de Salud/organización & administración , Organizaciones Responsables por la Atención/estadística & datos numéricos , Humanos , Medicare/legislación & jurisprudencia , Medicare/estadística & datos numéricos , Patient Protection and Affordable Care Act , Investigación Cualitativa , Prevención Secundaria/organización & administración , Encuestas y Cuestionarios , Estados Unidos
6.
Brachytherapy ; 8(3): 297-303, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19213608

RESUMEN

PURPOSE: Favorable dosimetric results have been reported using intraoperative inverse optimization (IO) for permanent prostate brachytherapy. The clinical implications of these improvements in dosimetry are unclear. We review toxicity and early biochemical outcomes for patients implanted using IO technique. METHODS AND MATERIALS: Between 2001 and 2007, 165 patients received permanent prostate implants using real-time IO and had >/=3 months of followup. Dose constraints for inverse planning were: the prostate volume receiving 100% of the prescription dose [prostate V(100)] was >95%; the dose received by 90% of the gland [prostate D(90)] was within the 140-180 by dose range; the volume of urethra receiving 150% of the prescription dose [urethra V(150)] was <30%; and the volume of rectal wall receiving 110% of the prescription dose [rectal V(110)] was <1.0 cc. Toxicity was prospectively scored using the Radiation Therapy Oncology Group toxicity scale and the International Prostate Symptom Score questionnaire. Biochemical control was determined using the nadir + 2 ng/mL definition. RESULTS: Mean followup was 30 months (range, 6-63 months). Risk classification was low risk in 89% and intermediate risk in 11%. Iodine-125 sources were used for 161 implants and palladium-103 sources for four implants. The median number of seeds and total activity implanted were 61 and 999 MBq, respectively, for a median prostate volume of 33.6 cc. Late GU and GI morbidity was uncommon. Among patients with at least 24 months followup, 16% had persistent Grade 2-3 urinary morbidity. Grade 2 rectal bleeding occurred in 1 patient (0.6%). Biochemical failure has occurred in only 4 patients at last followup. CONCLUSIONS: IO technique for prostate brachytherapy is associated with low rates of late morbidity and excellent early biochemical control. Additionally, the number of seeds and total implanted activity required to achieve a high-quality implant are lower compared with historical controls.


Asunto(s)
Braquiterapia/efectos adversos , Braquiterapia/métodos , Neoplasias de la Próstata/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Paladio , Antígeno Prostático Específico/sangre , Radioisótopos , Dosificación Radioterapéutica , Medición de Riesgo
7.
Brachytherapy ; 6(4): 238-45, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17991621

RESUMEN

PURPOSE: Comparison of inverse optimization (IO) to modified peripheral (MP) and geometric optimization (GO) intraoperative computer planning options for permanent seed implantation (PSI) of the prostate. METHODS AND MATERIALS: One hundred ten patients underwent PSI with iodine-125. Three computer planning options were compared including MP loading, GO, and IO. Preimplant dose goals (prescribed dose [PD] of 144 Gy) and normal tissue constraints were determined at the outset by the participating physicians before intraoperative computer planning. A single computer planning system was used for this comparison. Postimplant dosimetry was performed at 4-5 weeks and compared for V(100) and D(90), urethral V(150), and rectal V(110) of the PD. Acute urinary morbidity was evaluated and compared. RESULTS: All three options achieved a similar preimplant median V(100) (97%). The median number of needles and seeds implanted was greater with GO (29, 75) compared to MP (16, 66) and IO (17, 66) (p<0.0001 and p=0.0024, respectively). Postimplant dosimetry showed that IO achieved a higher percentage with V(100) >95% of the PD in multivariate analysis (p=0.04) and a lower percentage postimplant D(90) <140 Gy (7%) than for MP/GO (26%) (p = 0.01). IO predicted for lower urethral dose (p=0.0169), despite a higher median D(90) (169 Gy) than either MP (159 Gy) or GO (151 Gy) (p = 0.0025). The median percentage V(150) urethra for IO was 8% vs. 16% for MP and 23% for GO (p = 0.0005). With a median followup time of 6 months, acute Grade 2 urinary symptoms were higher with GO (81%) vs. MP (36%) and IO (53%) (p = 0.0019). CONCLUSIONS: Dosimetric outcomes for IO compare favorably to either MP or GO when performed in real time for PSI. In contrast to GO, IO and MP demonstrated excellent correlation between the intraoperative and postoperative plans while using fewer total and interior placed needles and seeds. IO appears feasible as an alternative intraoperative planning solution for PSI.


Asunto(s)
Braquiterapia/métodos , Próstata , Neoplasias de la Próstata/radioterapia , Planificación de la Radioterapia Asistida por Computador/métodos , Anciano , Humanos , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...